Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions

Annals of Neurology

Volumn 43, Issue 5, 1998, Pages 561-575

  Murer, M Gustavo ^a   Dziewczapolski, Gustavo ^b   Menalled, Liliana B ^b   García, M Carmen ^b   Agid, Yves ^a   Gershanik, Oscar ^b   Raisman Vozari, Rita ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

CARBIDOPA PLUS LEVODOPA; CARRIER PROTEIN; DOPAMINE 2 RECEPTOR; DOPAMINE TRANSPORTER; LEBOCAR; LEVODOPA; OXIDOPAMINE; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG; VESICULAR MONOAMINE TRANSPORTER 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASAL GANGLION; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; FEMALE; INNERVATION; INTRACEREBRAL DRUG ADMINISTRATION; NERVE CELL LESION; NEUROPROTECTION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; RECEPTOR UPREGULATION; SUBSTANTIA NIGRA; VENTRAL TEGMENTUM;

AMPHETAMINE; ANIMALS; ANTIPARKINSON AGENTS; APOMORPHINE; BEHAVIOR, ANIMAL; CARRIER PROTEINS; DISEASE MODELS, ANIMAL; DOPAMINE; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOPAMINE UPTAKE INHIBITORS; FEMALE; IODINE RADIOISOTOPES; LEVODOPA; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; NERVE FIBERS; NERVE TISSUE PROTEINS; NEUROPEPTIDES; NEUROTRANSMITTER AGENTS; OXIDOPAMINE; PARKINSON DISEASE, SECONDARY; PROSENCEPHALON; RADIOIMMUNOASSAY; RATS; RATS, WISTAR; SUBSTANTIA NIGRA; SULPIRIDE; SYMPATHOLYTICS; TYROSINE 3-MONOOXYGENASE; VENTRAL TEGMENTAL AREA; VESICULAR BIOGENIC AMINE TRANSPORT PROTEINS; VESICULAR MONOAMINE TRANSPORT PROTEINS;

EID: 0031968959     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.410430504     Document Type: Article

References (94)

1. Hirsch E, Graybiel AM, Agid Y. Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. Nature 1988;334:345-348
2. Jellinger K. The pathology of parkinsonism. In: Marsden CD, Fahn S, ed. Movement disorders, vol 2. London: Butterworths, 1987:124-165
3. Fahn S, Calne DB. Considerations in the management of parkinsonism. Neurology 1978;28:5-7
4. DeJong GJ, Meervaldt JD, Schmitz PIM. Factors that influence the occurrence of response variations in Parkinson's disease. Ann Neurol 1987;22:4-7
5. Lesser RP, Fahn S, Snider SR, et al. Analysis of the clinical problems in parkinsonism and the complications of long-term levodopa therapy. Neurology 1979;29:1253-1260
6. Sweet RD, McDowell FH. Five years' treatment of Parkinson's disease with levodopa: therapeutic results and survival of 100 patients. Ann Intern Med 1975;83:456-463
7. Yahr MD. Long-term levodopa in Parkinson's disease. Lancet 1977;1:706-707
8. Diamond SG, Markham CH, Hoehn MMM, et al. Multi-center study of Parkinson mortality with early vs later dopa treatment. Ann Neurol 1987;22:8-12
9. Hoehn MMM. Parkinson's disease: progression and mortality. Adv Neurol 1986;45:457-461
10. Martilla RJ, Rinne UK, Siirtola T, Sonninen V. Mortality of patients with Parkinson's disease treated with levodopa. J Neurol 1977;216:147-153
11. Joseph C, Chassan JB, Koch ML. Levodopa in Parkinson's disease: a long term appraisal of mortality. Ann Neurol 1978; 3:116-118
12. Zumstein H, Siegfried J. Mortality among Parkinson patients treated with L-DOPA combined with a decarboxilase inhibitor. Eur Neurol 1976;14:321-327
13. Uitti RJ, Ahlskog JE, Maraganore DM, et al. Levodopa therapy and survival in idiopathic Parkinson's disease: Olmsted County project. Neurology 1993;43:1918-1926
14. Kurtzke JF, Flaten TP, Murphy FM. Death rates from Parkinson's disease in Norway reflect increased survival. Neurology 1991;41:1665-1667
15. Clarke CE. Does levodopa therapy delay death in Parkinson's disease? A review of the evidence. Mov Disord 1995;10:250-256
16. Blanchet PJ, Allard P, Gregoire L, et al. Risk factots for peak dose dyskinesia in 100 levodopa-treated parkinsonian patients. Can J Neurol Sci 1996;23:189-193
17. Blin J, Bonnet A-M, Agid Y. Does levodopa aggravate Parkinson's disease? Neurology 1988;38:1410-1416
18. Cedarbaum JM, Gandy SE, McDowell FH. Early initiation of levodopa treatment does not promote the development of motor response fluctuations, dyskinesias or dementia in Parkinson's disease. Neurology 1991;41:622-629
19. Caraceni T, Scigliano G, Musicco M. The occurrence of motor fluctuations in parkinsonian patients treated long term with levodopa: role of early treatment and disease progression. Neurology 1991;41:380-384
20. Langston JW, Ballard P. Parkinsonism induced by MPTP: implications for treatment and the pathogenesis of Parkinson's disease. Can J Neurol Sci 1984;11:160-165
21. Burns SR, Pakkenberg H, Kopin IJ. Lack of progression of MPTP-induced parkinsonism during long-term treatment with L-DOPA. Ann Neurol 1985;18:117
22. Quinn NP, Parkes D, Janota I, Marsden CD. Case report: preservation of the substantia nigra and locus coeruleus in a patient receiving levodopa (2 g) plus decarboxilase inhibitor over a four-year period. Mov Disord 1986;1:65-68
23. Rajput AH, Fenton ME, Dhand A. Is levodopa toxic to non-degenerating substantia nigra cells? Clinical evidence. Neurology 1996;46: A371 (Abstract)
24. Yahr MD, Wolf A, Antunes J-L, et al. Autopsy findings in parkinsonism following treatment with levodopa. Neurology 1972; 22(Suppl):56-71
25. Melamed E. Initiation of levodopa therapy in parkinsonian patients should be delayed until the advanced stages of the disease. Arch Neurol 1986;43:402-405
26. Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1989; 321:1364-1371
27. Goetz CG. Dopaminergic agonists in the treatment of Parkinson's disease. Neurology 1990;40(Suppl 3):50-54
28. Olanow CW. Oxidation reactions in Parkinson's disease. Neurology 1990;40(Suppl 3):32-37
29. Rajput AH, Stern W, Laverty WH. Chronic low-dose levodopa therapy in Parkinson's disease: an argument for delaying levodopa therapy. Neurology 1984;34:991-996
30. Fahn S. Is levodopa toxic? Neurology 1996;47(Suppl 3):S184-S195
31. Michel PP, Hefti F. Toxicity of 6-hydroxydopamine and dopamine for dopaminergic neurons in culture. J Neurosci Res 1990;26:428-435
32. Tanaka M, Sotomatsu A, Kanal H, Hirai S. Dopa and dopamine cause cultured neuronal death in the presence of iron. J Neurol Sci 1991;101:198-203
33. Mena MA, Pardo B, Casarejos MJ, et al. Neurotoxicity of levodopa on catecholamine-rich neurons. Mov Disord 1992;7: 23-31
34. Mena MA, Pardo B, Paino CL, de Yebenes JG. Levodopa toxicity in foetal rat midbrain neurons in culture: modulation by ascorbic acid. Neuroreport 1993;4:438-440
35. Mytilineou C, Han SK, Cohen G. Toxic and protective effects of L-DOPA on mesencephalic cell cultures. J Neurochem 1993; 61:1470-1478
36. Walkinshaw G, Waters CM. Induction of apoptosis in catecholaminergic PC12 cells by L-DOPA: implications for the treatment of Parkinson's disease. J Clin Invest 1995;95:2458-2464
37. Graham DG. Oxidative stress for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol Pharmacol 1978; 14:633-643
38. Graham DG, Tiffany SM, Bell WR Jr, Gutknetcht WF. Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine, and related compounds toward C1300 neuroblastoma cells in vitro. Mol Pharmacol 1978;14:644-653
39. Spencer JPE, Jenner A, Butler J, et al. Evaluation of the prooxidant and anti-oxidant actions of L-DOPA and dopamine in vitro: implications for Parkinson's disease. Free Radic Res Commun 1996;24:95-105
40. Zigmond MJ, Hastings TG, Abercrombie ED. Neurochemical responses to 6-OHDA and L-DOPA therapy: implications for Parkinson's disease. Ann NY Acad Sci 1992;648:71-86
41. Spencer-Smith T, Parker WD Jr, Bennett JP Jr. L-DOPA increases nigral production of hydroxyl radicals in vivo: potential L-DOPA toxicity? Neutoreport 1994;5:1009-1011
42. Obata T, Yamanaka Y. Protective effect of carbidopa on hydroxyl radical generation in the rat striatum by dopamine. Neurosci Lett 1996;221:13-16
43. Ogawa N, Asanuma M, Kondo Y, et al. Differential effects of chronic L-DOPA treatment on lipid peroxidation in the mouse brain with or without pretreatment with 6-OHDA. Neurosci Lett 1994;171:55-58
44. Hastings TG, Lewis DA, Zigmond MJ. Role of oxidation in the neurotoxic effects of intrastriatal dopamine injections. Proc Natl Acad Sci USA 1996;93:1956-1961
45. Olney JW, Zorumski CF, Stewart GR, et al. Excitotoxicity of L-DOPA and 6-OH-DOPA: implications for Parkinson's and Huntington's diseases. Exp Neurol 1990;108:269-272
46. Newcomer TA, Rosenberg PA, Aizenman E. TOPA quinone, a kainate-like agonist and excitotoxin, is generated by a catecholaminergic cell line. J Neurosci 1995;15:3172-3177
47. Pardo B, Mena MA, de Yebenes JG. L-DOPA inhibits complex I of the electron transport chain in catecholamine-nch human neuroblastoma NB69 cells. J Neurochem 1995;64:576-582
48. Przedborski S, Jackson-Lewis V, Muthane U, et al. Chronic L-DOPA administration alters cerebral mitochondrial respiratory chain activity. Ann Neurol 1993;34:715-723
49. Cooper JM, Daniel SE, Marsden CD, Schapira AHV. L-DOPA and complex I deficiency in Parkinson's disease brain. Mov Disord 1995;10:295-297
50. Cotzias GC, Miller ST, Nicholson AR, et al. Prolongation of the life-span in mice adapted to large amounts of L-DOPA. Proc Natl Acad Sci USA 1974;71:2466-2469
51. Hefti F, Melamed E, Bhawan J, Wurtmen RL. Long-term administration of L-DOPA does not damage dopaminergic neurons in the mouse. Neurology 1981;31:1194-1195
52. Perry TL, Yong VW, Foulks JG, et al. Nigrostriatal dopaminergic neurons remain undamaged in rats given high doses of L-DOPA and carbidopa chronically. J Neurochem 1984;43: 990-993
53. Blunt SB, Jenner P, Marsden CD. Suppressive effect of L-DOPA on dopamine cells remaining in the ventral tegmental area of rats previously exposed to the neurotoxin 6-hydroxydopamine. Mov Disord 1993;8:129-133
54. Steece-Collier K, Sladeck CD, Sladek JR Jr. Chronic levodopa impairs morphological development of grafted embryonic dopamine neurons. Exp Neurol 1990;110:201-208
55. Blunt SB, Jenner P, Marsden CD. The effect of L-DOPA and carbidopa treatment on the survival of rat fetal dopamine grafts assessed by tyrosine hydroxylase immunohistochemistry and [3H]mazindol autoradiography. Neuroscience 1991;43:95-110
56. Filloux F, Townsend JJ. Pre- and postsynaptic neurotoxic effects of dopamine demonstrated by intrastriatal injection. Exp Neurol 1993;119:79-88
57. Schneider JS. Levodopa-induced dyskinesias in parkinsonian monkeys: relationship to extent of nigrostriatal damage. Pharmacol Biochem Behav 1989;34:193-196
58. Abercrombie ED, Bonatz AE, Zigmond MJ. Effects of L-DOPA on extracellular dopamine in striatum of normal and 6-OHDA-treated rats. Brain Res 1990;525:36-44
59. Hefti F, Melamed E, Wurtman RJ. Partial lesions of the dopaminergic nigrostriatal system in rat brain: biochemical-characterization. Brain Res 1980;195:123-137
60. Raisman-Vozari R, Hirsch E, Javoy-Agid F, et al. Quantitative autoradiography of tyrosine-hydroxylase immunoreactivity in the rat brain. J Neurochem 1991;57:1212-1222
61. Dziewczapolski G, Murer MG, Agid Y, et al. Absence of neurotoxicity of chronic L-DOPA in 6-hydroxydopamine-lesioned rats. Neuroreport 1997;8:975-979
62. Paxinos G, Watson C. The rat brain in stereotaxic coordinates. New York: Academic Press, 1986
63. Naudon L, Raisman-Vozari R, Edwards RH, et al. Reserpine affects differentially the density of the vesicular monoamine transporter and dihydroretrabenzine binding sites. Eur J Neurosci 1996;8:842-846
64. Peter D, Liu Y, Starmini C, et al. Differential expression of two vesicular monoamine transporters. J Neurosci 1995;15:6179-6188
65. Freed C, Revay R, Vaughan RA, et al. Dopamine transporter immunoreactivity in the rat brain. J Comp Neurol 1995;19: 222-226
66. Blanchard V, Raisman-Vozari R, Savasta M, et al. Cellular quantification of tyrosine-hydroxylase in the rat brain by immunoautoradiography. J Neurochem 1993;61:617-626
67. 125I]sulpiride. Neuroscience 1987;20:117-155
68. Blanchard V, Chritin M, Vyas S, et al. Long-term induction of tyrosine-hydroxylase expression: compensatory response to partial degeneration of the dopaminergic nigrostriatal system in the rat brain. J Neurochem 1995;64:1669-1679
69. Salin P, Dziewczapolski G, Gershanik O, et al. Differential regional effects of long-term L-DOPA treatment on preproenkephalin and preprotachykinin gene expression in the striatum of 6-hydroxydopamine-lesioned rats. Mol Brain Res 1997;47: 311-321
70. Agid Y, Javoy F, Glowinski J. Hyperactivity of remaining dopaminergic neurons after partial destruction of the nigrostriatal dopaminergic system in the rat. Nat New Biol 1973;245:150-151
71. Seroogy KB, Gall CM. Expression of neurotrophins by midbrain dopaminergic neurons. Exp Neurol 1993;124:119-128
72. Blanchard V, Anglade P, Dziewczapolski G, et al. Dopaminergic sprouting in the rat striatum after partial lesion of the substantia nigra. Brain Res 1996;709:319-325
73. Vos PE, Steinbusch HWM, Van Ree JM. Reinnervation after destruction of the dopaminergic system in the rat nucleus accumbens: a quantitative immunohistochemical analysis. Neurosci Lett 1996;207:21-24
74. Bing G, Zhang Y, Watanabe Y, et al. Locus coeruleus lesions potentiate neurotoxic effects of MPTP in dopaminergic neurons of the substantia nigra. Brain Res 1994;668:261-265
75. Mavridis M, Degryse A-D, Lategan AJ, et al. Effects of locus coeruleus lesions on parkinsonian signs, striatal dopamine and substantia nigra cell loss after MPTP in monkeys: a possible role for the locus coeruleus in the progression of Parkinson's disease. Neuroscience 1991;41:507-523
76. Han S-K, Mytilineou C, Cohen G. L-DOPA up-regulates glutathione and protects mesencephalic cultures against oxidative stress. J Neurochem 1996;66:501-510
77. Mena MA, Bogulavsky J, Ryjak I, et al. Neurotrophic effects of L-DOPA in postnatal midbrain dopamine cortical astrocyte co-culture. Soc Neurosci Abstr 1996;22:533 (Abstract)
78. Hansen JT, Sakai K, Greenamyre JT, Moran S. Sprouting of dopaminergic fibers from spared mesencephalic dopamine neurons in the unilateral partial lesioned rat. Brain Res 1995:670: 197-204
79. Bowenkamp KE, David D, Lapchack PL, et al. 6-Hydroxydopamine induces the loss of the dopaminergic phenotype in substantia nigra neurons of the rat. A possible mechanism for restoration of the nigrostriatal circuit mediated by glial cell line-derived neurotrophic factor. Exp Brain Res 1996;111-17
80. Sauer H, Oertel WH. Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: a combined retrograde tracing and immunocytochemical study in the rat. Neuroscience 1994;59:401-415
81. DeVitry F, Hillion J, Catelon J, et al. Dopamine increases the expression of tyrosine hydroxylase and aromatic amino acid decarboxylase in primary cultures of fetal neurons. Dev Brain Res 1991;59:123-131
82. Sauer H, Wong V, Bjorklund A. Brain-derived neurotrophic factor and neurotrophin-4/5 modify neurotransmitter-related gene expression in the 6-OHDA lesioned rat striatum. Neuroscience 1995;65:927-933
83. Jeon BS, Jackson-Lewis V, Burke RE. 6-Hydroxydopamine lesion of the rat substantia nigra: time course and morphology of cell death. Neurodegeneration 1995;4:131-137
84. Okazawa H, Murata M, Watanabe M, et al. Dopaminergic stimulation up-regulates the in vivo expression of BDNF in the striatum. FEBS Lett 1992;313:138-142
85. Carvey PM, Ptak LR, Lo ES, et al. Levodopa reduces the growth promoting effects of striatal extracts on rostral mesencephalic tegmentum cultures. Exp Neurol 1991;114:28-34
86. Carvey PM, Ptak LR, Nath ST, et al. Striatal extracts from patients with Parkinson's disease promote dopamine neuron growth in mesencephalic cultures. Exp Neurol 1993;120:149-152
87. Fahn S, Cohen G. The oxidative stress hypothesis in Parkinson's disease: evidence supporting it. Ann Neurol 1992;32: 804-812
88. France-Lanord V, Brugg B, Michel PP, et al. Mitochondrial free radical signal in ceramide-dependent apoptosis: a putative mechanism for neuronal death in Parkinson's disease. J Neurochem 1997;69:1612-1621
89. Calne DB. The free radical hypothesis in idiopathic Parkinson's disease: evidence against it. Ann Neurol 1992;32:799-803
90. Olanow CW, Fahn S, Langston JW, Godbold J. Selegiline and mortality in Parkinson's disease. Ann Neurol 1996;40:841-845
91. Parkinson Study Group. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP subjects not requiring levodopa. Ann Neurol 1996;39:29-36
92. Parkinson Study Group. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Ann Neurol 1996;39:37-45
93. Roos RAC, Vredevoogd CB, van der Velde EA. Response fluctuations in Parkinson's disease. Neurology 1990;40:1344-1346
94. Nutt JG, Carter JH, Woodward WR. Long-duration response to levodopa. Neurology 1995;45:1613-1616